Theravance Biopharma, Inc.
KYFinancials
Valuation Metrics
Theravance Biopharma, Inc.'s Market Cap is $878M. At end of 2025 it was $952M. Ranked #2536 of 3,121 in US market (top 81%), #1055 of 1,463 on NASDAQ (top 72%), #195 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $878M | US#2,536/3,121 Sec#195/266 |
| Revenue | $104M | US#2,694/3,121 Sec#126/266 |
| Net Income | $54M | US#1,862/3,121 Sec#62/266 |
| Total Assets | $470M | US#2,797/3,121 Sec#173/266 |
| Net Assets | $290M | US#2,537/3,121 Sec#159/266 |
| Employees | 90 | US#2,649/3,121 Sec#186/266 |
| Value | ||
| P/E | 16.33x | US#867/3,121 Sec#28/266 |
| P/B | 3.03x | US#1,760/3,121 Sec#86/266 |
| PEG | 0.05x | US#131/3,121 Sec#9/266 |
| P/S | 8.42x | US#2,626/3,121 Sec#105/266 |
| EV/EBITDA | 10.19x | US#842/3,121 Sec#24/266 |
| FCF Yield | 5.90% | US#1,230/3,121 Sec#37/266 |
| Profitability | ||
| ROE | 18.57% | US#665/3,121 Sec#34/266 |
| ROA | 11.45% | US#378/3,121 Sec#28/266 |
| Op. Margin | 4.46% | US#2,036/3,121 Sec#72/266 |
| Revenue Growth | 35.11% | US#351/3,121 Sec#56/266 |
| Earnings Growth | 312.92% | US#109/3,121 Sec#7/266 |
| Financial Health | ||
| Debt Ratio | 62.15% | US#686/3,121 Sec#147/266 |
| Total Debt | $39M | US#2,656/3,121 Sec#165/266 |
| FCF | $52M | US#1,979/3,121 Sec#69/266 |
| Cash | $220M | US#1,659/3,121 Sec#103/266 |
| Current Ratio | 13.54x | US#189/3,121 Sec#59/266 |
| Net Debt/EBITDA | -2.65x | US#138/3,121 Sec#11/266 |
| Performance | ||
| 1Y Return | 21.28% | US#1,122/3,121 Sec#153/266 |
| 1M Return | 0.53% | US#883/3,121 Sec#86/266 |
| From 52W High | -18.97% | US#1,437/3,121 Sec#103/266 |
| 1Y MDD | -34.57% | US#1,712/3,121 Sec#114/266 |
| Trading | ||
| Volume | 305,201 shares | US#2,393/3,121 Sec#235/266 |
| Trading Value | $5M | US#2,646/3,121 Sec#220/266 |
| Per Share | ||
| EPS | $1.04 | US#1,664/3,121 Sec#47/266 |
| BPS | $5.62 | US#2,233/3,121 Sec#121/266 |
Company Info
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.